Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma. Retrospective analysis.

CONCLUSIONS: Capecitabine and temozolomide combination is effective treatment for patients with grade 3 neuroendocrine tumours with Ki-67 index ranging between 20 and 54%. The treatment did not overcome aggressive character of neuroendocrine carcinomas and resulted is low response and survival outcomes in comparison to those achieved in tumours therapy. PMID: 30843182 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30843182?dopt=Abstract

Source: Endokrynologia Polska - March 6, 2019 Category: Endocrinology Authors: Rogowski W, Wachuła E, Gorzelak A, Lebiedzińska A, Sulżyc-Bielicka V, Iżycka-Świeszewska E, Żołnierek J, Kos-Kudła B Tags: Endokrynol Pol Source Type: research